Recent Updates
Recently added Catalysts
MLYS Positive Sentiment Score: 65/100

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025

Wednesday, February 5, 2025 1 min read
Key Takeaway: Mineralys Therapeutics, a clinical-stage biopharmaceutical company, will announce its fourth quarter and full year 2024 financial results on February 12, 2025. The company specializes in developing medicines for health conditions driven by dysregulated aldosterone, including hypertension and chronic kidney disease. A conference call will follow the announcement, offering insights into the company's performance. This event underscores Mineralys's commitment to transparency and engagement with its investors.

Market Sentiment Analysis

POSITIVE FACTORS

  • Mineralys Therapeutics is poised to report its financial results, indicating potential growth and transparency in operations.
  • The company focuses on significant health issues such as hypertension and CKD, which could reflect a strong market position.

Full Press Release Details

RADNOR, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2024, before the financial markets open on Wednesday, February 12, 2025.
Wednesday, February 12 th @ 8:30 a.m. ET
Domestic: 1-800-717-1738
International: 1-646-307-1865
Webcast: Link
A live webcast of the conference call may also be found on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.
investorrelations@mineralystx.com
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com

Frequently Asked Questions

When will Mineralys report its financial results?

Mineralys will report its financial results on February 12, 2025.

What diseases does Mineralys Therapeutics target?

Mineralys focuses on hypertension, chronic kidney disease, and obstructive sleep apnea.

What is lorundrostat?

Lorundrostat is a selective aldosterone synthase inhibitor developed by Mineralys.

Where is Mineralys Therapeutics located?

Mineralys Therapeutics is based in Radnor, Pennsylvania.

How can I join the conference call?

Dial 1-800-717-1738 for domestic or 1-646-307-1865 for international access.

Tags: MLYS Viatris Investor Conferences Healthcare Mineralys Therapeutics hypertension chronic kidney disease conference call
Last updated: Feb 5, 2025